Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner, SM; Melchardt, T; Egle, A; Magnes, T; Skrabs, C; Staber, P; Simonitsch-Klupp, I; Panny, M; Lehner, B; Greil, R; Keil, F; Jäger, U; Sillaber, C.

Eur J Haematol. 2020; 104(3):251-258.

/https://pubmed.ncbi.nlm.nih.gov/31838747/